April 9, 2025: MaaT Pharma reports safety interim analysis from trial of microbiome therapy - Clinical Trials Arena - MaaT Pharma

To read the article, click here!

Previous PostApril 14, 2025: Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)
Next PostApril 9, 2025: Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients - OncLive

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club